Drug Trial Radar · NCT07462143
A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
May 12, 2026
Primary completion
May 12, 2027
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- RemeGen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ⅱ/Ⅲ study. The purpose of this study is to evaluate the efficacy and safety of RC148 combined with chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (CRC)
Conditions
- Colorectal (Colon or Rectal) Cancer
Interventions
RC148 (Dose 1) plus Capecitabine and OxaliplatinDrug
RC148 (Dose 1) plus Capecitabine and Oxaliplatin
RC148 (Dose 2) plus Capecitabine and OxaliplatinDrug
RC148 (Dose 2) plus Capecitabine and Oxaliplatin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: 24 months
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Recruiting
Meizhou People's Hospital
Meizhou, Guangdong, China · Recruiting
Guangxi Medical University Cancer Hospital
Nanjing, Guangxi, China · Recruiting
The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital
Shijiazhuang, Hebei, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Tongji Medical College of Huazhong University of Science &Technology
Wuhan, Hubei, China · Recruiting
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China · Recruiting
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China · Recruiting
The first hospital of Jilin University
Changchun, Jilin, China · Recruiting
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Shanxi Cancer Hospital
Taiyuan, Shanxi, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
People's Hospital of Tianjin
Tianjin, Tianjin Municipality, China · Recruiting
Yunnan Cancer Hospital
Kunming, Yunnan, China · Recruiting
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.